دورية أكاديمية
أعرض في EDS

mTOR Inhibitors in the Treatment of Cancer

التفاصيل البيبلوغرافية
العنوان: mTOR Inhibitors in the Treatment of Cancer
المؤلفون: Özcan, Özge, Dikmen, Miriş
المساهمون: Anadolu Üniversitesi, Eczacılık Fakültesi, Farmakoloji Anabilim Dalı, Dikmen, Miriş
بيانات النشر: Marmara University, Fac Pharmacy
سنة النشر: 2015
المجموعة: Anadolu University Institutional Repository
مصطلحات موضوعية: Mtor Inhibitors, Pi3K/Akt, Cancer, Rapamycin
الوصف: WOS: 000365086900015 ; The mammalian target of rapamycin (mTOR) is a highly conserved in evolution serine/threonine kinase belonging to the phosphatidylinositol kinase related protein kinases family. mTOR plays a central role in regulation of a number of cellular function inculuding especialy cell growth, metabolism and proliferation and in ensuring cellular homeostasis. Once of basic signalling pathway that has been described as important in cancer including phosphatidylinositol 3-kinase (PI3K)/AKT/kinase cascade. These pathway are frequently deteriorated in cancer, and therefore mTOR inhibition is a important antitumor target. mTOR inhibitors include rapamycin (i.e. sirolimus) and its derivatives; temsirolimus, everolimus and deforolimus (ridaforolimus). Rapamycin and analogs inhibit proliferation of cancer cells in both in vitro and in vivo. mTOR inhibitors have the important potential to provide anticancer activity in many tumor types.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 1309-0801
العلاقة: Marmara Pharmaceutical Journal; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://dx.doi.org/10.12991/mpj.201519394607Test; https://hdl.handle.net/11421/13197Test; 19; 290; 297
DOI: 10.12991/mpj.201519394607
الإتاحة: https://doi.org/10.12991/mpj.201519394607Test
https://hdl.handle.net/11421/13197Test
حقوق: info:eu-repo/semantics/closedAccess
رقم الانضمام: edsbas.6C014615
قاعدة البيانات: BASE
الوصف
تدمد:13090801
DOI:10.12991/mpj.201519394607